Yipinhong Pharmaceutical Co Ltd Class A (300723) - Total Liabilities
Based on the latest financial reports, Yipinhong Pharmaceutical Co Ltd Class A (300723) has total liabilities worth CN¥2.73 Billion CNY (≈ $399.62 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Yipinhong Pharmaceutical Co Ltd Class A (300723) cash flow conversion to assess how effectively this company generates cash.
Yipinhong Pharmaceutical Co Ltd Class A - Total Liabilities Trend (2013–2024)
This chart illustrates how Yipinhong Pharmaceutical Co Ltd Class A's total liabilities have evolved over time, based on quarterly financial data. Check Yipinhong Pharmaceutical Co Ltd Class A liquidity resilience to evaluate the company's liquid asset resilience ratio.
Yipinhong Pharmaceutical Co Ltd Class A Competitors by Total Liabilities
The table below lists competitors of Yipinhong Pharmaceutical Co Ltd Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
|
USA | $370.09 Million |
|
Jiangsu Lopal Tech Co Ltd
SHG:603906
|
China | CN¥14.61 Billion |
|
Zhuzhou Kibing Group Co Ltd
SHG:601636
|
China | CN¥20.96 Billion |
|
Tianma Microelectronics Co Ltd
SHE:000050
|
China | CN¥47.30 Billion |
|
Piramal Enterprises Limited
NSE:PEL
|
India | Rs-270.96 Billion |
|
Zibo Qixiang Tengda Chemical Co Ltd
SHE:002408
|
China | CN¥13.08 Billion |
|
Exxaro Resources Ltd
JSE:EXX
|
South Africa | ZAC31.96 Billion |
|
Boralex Inc
TO:BLX
|
Canada | CA$5.68 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Yipinhong Pharmaceutical Co Ltd Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Yipinhong Pharmaceutical Co Ltd Class A.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yipinhong Pharmaceutical Co Ltd Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yipinhong Pharmaceutical Co Ltd Class A (2013–2024)
The table below shows the annual total liabilities of Yipinhong Pharmaceutical Co Ltd Class A from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.47 Billion ≈ $361.18 Million |
+36.56% |
| 2023-12-31 | CN¥1.81 Billion ≈ $264.48 Million |
-6.48% |
| 2022-12-31 | CN¥1.93 Billion ≈ $282.81 Million |
+14.63% |
| 2021-12-31 | CN¥1.69 Billion ≈ $246.72 Million |
+159.33% |
| 2020-12-31 | CN¥650.14 Million ≈ $95.14 Million |
+43.14% |
| 2019-12-31 | CN¥454.20 Million ≈ $66.46 Million |
-5.70% |
| 2018-12-31 | CN¥481.67 Million ≈ $70.48 Million |
+28.98% |
| 2017-12-31 | CN¥373.45 Million ≈ $54.65 Million |
-10.19% |
| 2016-12-31 | CN¥415.82 Million ≈ $60.85 Million |
-3.28% |
| 2015-12-31 | CN¥429.90 Million ≈ $62.91 Million |
-29.09% |
| 2014-12-31 | CN¥606.28 Million ≈ $88.72 Million |
+168.67% |
| 2013-12-31 | CN¥225.66 Million ≈ $33.02 Million |
-- |
About Yipinhong Pharmaceutical Co Ltd Class A
ApicHope Pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of pharmaceutical drugs in China. The company offers pediatric medicines, such as fuganlin and yiqi jianpi oral liquids, carboxymestrine oral solutions, and xiao'er kechuanling oral liquid products; and clindamycin palmitate hydrochloride dispersible tablets, acetylkitasamycin for suspension, qinxia… Read more